Ruti Aga: Six Years, One Forged Prescription, and the Medical Vacuum That Ended a Marathon Career

The number arrives first: six years. But the heaviest object in this story is not a number. It is a piece of paper — a prescription written on the pad of a clinic that did not exist. Ruti Aga has been banned for six years by the Athletics Integrity Unit. Two years for the presence of a prohibited substance in the sample taken after she won a half marathon in China in March. Four years for tampering with the evidence submitted to explain it. That second half is what separates this from an ordinary doping case. At 32, a six-year suspension means a return at 38. In the depth of Ethiopian women's marathon running, a 38-year-old with a doping record is not a selection question — it is a closed file. Which is why the arithmetic deserves a closer look: this ban did not become six years because of a drug. It became six years because of a document. I build the frame first, then let the outlier speak. Here the outlier is not the injection. It is the paperwork. Aga's record is genuinely elite. She won the 2026 Tokyo Marathon, a World Marathon Major. She was second in Berlin in 2026. Three second-place finishes at Majors in total. Public records place her best at roughly 2:18:34 in Berlin 2026 and 2:20:40 in Tokyo 2026 — figures absent from the original report and worth holding as estimates rather than confirmed marks. What is confirmed is that she won a half marathon in China in March, and that the sample was collected there. No time, no splits, no field strength has been published. The AIU statement came on Thursday. It carries the six-year figure, a start date of 10 September, and one sentence that anchors everything: the prescription submitted to justify treatment for a knee injury was forged. A technical correction is required here, and it is not a matter of vocabulary. Several reports described methylprednisolone as a prohibited steroid and stated that WADA classifies it as performance-enhancing. That is imprecise. Methylprednisolone is a glucocorticoid — class S9 on the WADA Prohibited List — not an anabolic steroid, which is class S1. S9 substances are prohibited in-competition only, and only by injection, oral or rectal routes. The consequence is decisive: a therapeutic knee injection given out-of-competition is entirely lawful. It becomes a violation only if residues are present in an in-competition sample. The case therefore never turned on steroid use. It turned on route and timing — which route, and how many days before the race. That is precisely why the case was defensible. An athlete with documented knee synovitis had three legitimate paths. First, genuine medical records: date, dose, route, and the prescribing physician's registration number. Second, a Therapeutic Use Exemption applied for in advance. Third, correct washout timing, so that no residue remained at the race. None of the three was taken. A prescription was manufactured instead. And it failed in three separate places. The clinic named on the document did not exist. The person who wrote it was a family member with no medical registration. That person claimed to have used an old prescription pad from a former workplace — a claim the clinic in question disowned. Every match sheet is a ritual: observe, record, then doubt. The AIU doubted, and three independent verification failures pointed the same way. This was not a filing error. It is the signature of an athlete operating without a credentialed team physician. The arithmetic is where the case becomes legible. Two years for presence, four for tampering. The four-year figure is the Code's standard tampering sanction — unremarkable. The remarkable part is the two: it means the panel rejected the no-significant-fault mitigation that could have reduced the presence sanction. Once a forged document enters a defence, that mitigation closes. A person who fabricates evidence cannot credibly claim inadvertence. There is a paradox worth naming. Forged documentation is itself circumstantial evidence of intent to conceal — yet it did not aggravate the presence sanction. It was routed into a separate four-year penalty and added. The panel kept the two offences in two boxes and summed them. Backdating the ban to 10 September is procedural, not a reduction. Provisional suspension time counts against the sanction. Nothing is gained in real terms; only a date moves. The unstated consequence is almost certainly this: the March race result and its prize money will be annulled, and ranking points accrued after that date will go with them. What survives is the 2026 Tokyo title and the three Major runner-up finishes. The ban attaches to the March race; absent evidence of earlier use, results before it stand. That is the remaining asset of a genuinely elite career. The root cause is the knee, and it is a systemic signal rather than an individual failing. Chronic knee pathology is an occupational condition for high-volume marathoners. The pressure to mask pain is real, because income flows through appearance fees — missing one race weakens the next negotiation. Glucocorticoids are the cheapest available answer: they reduce pain, cut inflammation, and, given out-of-competition, are lawful. A legal tool, an illegal incentive, and no credentialed medical adviser in between. That vacuum is the least-discussed element of doping cases. An athlete at 2:18 level, with three Major podiums, had no doctor who owned a prescription pad. When medical support is informal, documentation becomes informal. And when documentation is informal, forgery stops being a distant possibility and becomes the next logical step. The most telling detail is that the tampering sanction came from an interview, not from a document alone — from statements made under questioning. That matters, because language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention. When a large share of a sanction rests on oral statements, that question becomes legally live. The economics complete the picture. For East African marathoners, the Chinese label-race circuit is a distinct income tier: lower risk than a Major, decent fees, comparatively little media attention. It is also the AIU's highest-yield testing ground in recent years. Two economies now collide inside the same race. The appearance-fee economy says run, be seen, get paid. The testing economy says the sample will be collected here. A 32-year-old standing at that intersection with a sore knee has one weak link — and it is her medical circle. The competitive picture is almost entirely unaffected, and that should be said plainly. Removing a 2:18–2:20 athlete from Ethiopian women's marathon running does not move national selection arithmetic. Her three Major second places were commercial-tier results, not championship conversions; she holds no global championship medal. In a pool that deep, one absence is invisible. What is visible is a pattern. The clustering of AIU road-running cases involving tampering suggests the enforcement frontier has shifted from detection to document verification. Aga's case is the cleanest illustration: the underlying violation was minor, and it became major because the explanation was manufactured. Here is where I am least comfortable, and I will not hide it. Six years for a substance with no proven endurance benefit is an uncomfortable number. Compare it to the four-year standard applied in erythropoietin cases. A glucocorticoid whose primary function is reducing inflammation has produced a longer ban than the drugs that actually move a marathon time. I am not arguing the sanction is wrong. Four years for tampering is standard, and fabricating a document is not a technicality — it is a deliberate attempt to deceive the system. I am arguing that this penalty was set by a governance failure rather than by a drug dose, and that the governance failure was the element least within the athlete's control. Which raises the second uncomfortable question. The AIU statement names only the family member who wrote the prescription. Nothing is said about the agent, manager or training group that either advised the step or accepted the document. Whether a 32-year-old makes that decision alone is a question worth asking, and it remains unanswered. A further layer goes unaddressed: document forgery can be a criminal matter. The AIU's jurisdiction is disciplinary; no referral to national authorities appears in the statement. That silence leaves the case unfinished. There is a lesson here that travels, including to the country I write from. Indian athletics has rebuilt its funding architecture — TOPS, Khelo India, the sports-quota jobs at Railways, Services and state police. Funding and medical governance, however, are different things. An athlete can have a coach, a physio and a foreign camp, and still have no doctor accountable for a prescription. Aga's case is the price of that gap. What makes this case worth remembering is not the drug. It is how a defensible situation — knee treatment, out-of-competition, lawful route — became a six-year ban. The answer is three words long: documents, documents, documents. So the next time a label-race result sheet appears, do not read only the time. Ask how many athletes in that field had a credentialed team doctor, and how many had only a phone number. That question will never appear on the results page. But the next six-year ban is probably hiding inside its answer.